Merck KGaA (ETR: MRK) announced fiscal year 2025 results, recording €21.102 billion (~$24.5 billion) in net sales with 3.1% organic growth, offset by –3.7% foreign exchange drag from U.S. dollar and Asian currency weakness. The Healthcare division delivered solid 3.7% organic growth to €8.6 billion, with SpringWorks acquisition contributing 2.2% portfolio effect and all franchises recording positive momentum.
FX Sensitivity: 45% of sales USD-denominated; 2026 hedge positions partially offsetting currency risk
2026 Guidance & Investor Outlook
Metric
Guidance
Implication
Net Sales
€20.0–21.1 billion
Flat to slight growth; FX headwinds persist
Organic Growth
–1% to +2%
Rare Diseases ramping; CM&E normalization
EBITDA Margin
Stable
Cost discipline offsetting R&D investment
Key Catalysts
Pimicotinib approval; Ogsiveo ex-U.S. launches
Pipeline execution critical to guidance achievement
Forward‑Looking Statements This brief contains forward‑looking statements regarding 2026 financial performance, Rare Diseases franchise growth, and currency expectations based on Merck KGaA’s 2025 disclosures. Actual results may differ due to competitive dynamics, regulatory approvals, and foreign exchange volatility.-Fineline Info & Tech
By Fineline Cube 